MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia

MorphoSys Announces First Scientific Publication on  Novel Antibody Platform 
Ylanthia 
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwired) -- 05/10/13
--  MorphoSys  AG (FSE: MOR; Prime Standard  Segment; TecDAX)
announced today that a first  scientific  publication  on  the 
Company's  novel,  proprietary antibody
platform  Ylanthia was 
published in  the current  issue of  "mAbs". The article
titled  "A 
fully  synthetic  human  Fab  antibody  library based on fixed
VH/VL
framework  pairings  with  favorable  biophysical  properties"
describes for the first  time the detailed design, generation and
testing of the Ylanthia library.
Ylanthia became commercially
available for existing and new partners in 2012 and is currently used
in two commercial agreements. 
"Ylanthia sets new standards for therapeutic antibody generation. Its
unique and innovative  design translates  into unprecedented 
structural diversity which is expected   to  result  in  antibodies 
against  previously  inaccessible target
molecules  and  covering  a 
unique  epitope  space. Furthermore, our scientists
introduced  an
entirely new concept  to improve biophysical characteristics that
are
 relevant for antibody selection,  manufacturing and administration,
finally
leading to better drugs," commented Dr. Marlies Sproll, Chief
Scientific Officer
of MorphoSys AG. 
To confirm the functionality and quality of the Ylanthia antibody
library, phage
selections   against   several  antigens  were 
performed.  Subsequent antibody
characterization revealed broad
diversity and significantly improved biophysical
properties 
including a  very low  aggregation tendency, increased
thermodynamic
stability and favorable solubility of Ylanthia
antibodies. 
Ylanthia comprises more than 100 billion distinct, fully human
antibodies, which
makes  it the industry's  largest known antibody 
Fab library. It uses 36 fixed,
naturally-occurring   heavy   and 
light  chain  framework  combinations, which
translates  into very
broad structural diversity. Ylanthia's antibody frameworks
were 
pre-selected for  favorable expression  levels, stability  and
aggregation
behavior.  A shift towards  higher stability and  stress
tolerance will increase
shelf  life and serum stability of resulting
antibody products, m
aking them more
cost-effective  to produce. A 
higher solubility in  turn opens up  the path for more convenient
ways of administration, to the benefit of patients. When
needed,
antibodies from the Ylanthia library are optimized using
MorphoSys's proprietary
Slonomics technology. Slonomics enables
optimization of Ylanthia antibodies with
unprecedented speed and
flexibility. 
The full paper is available on 
http://www.landesbioscience.com/journals/mabs/article/24218/ 
About MorphoSys: 
MorphoSys developed HuCAL, the most successful antibody library
technology in
the pharmaceutical industry. By successfully applying
this and other patented
technologies, MorphoSys has become a leader
in the field of therapeutic antibodies, one of the fastest-growing
drug classes in human healthcare. Together with its pharmaceutical
partners, MorphoSys has built a therapeutic
pipeline of more than 70
human antibody drug candidates for the treatment of
cancer,
rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With
its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under
the symbol MOR. For regular updates
about MorphoSys, visit
http://www.morphosys.com. 
HuCAL(R),  HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R),
RapMAT(R), arYla(R), Ylanthia(R) and  100 billion  high 
potentials(R)  are registered trademarks of MorphoSys AG. 
Slonomics(R)  is  a  registered  trademark  of  Sloning 
BioTechnology GmbH,  a subsidiary of MorphoSys AG. 
This 
communication contains  certain forward-looking  statements
concerning the MorphoSys  group of  companies. The  forward-looking
statements contained herein
represent  the judgment of MorphoSys as
of  the date of this release and involve
risks  and  uncertainties. 
Should  actual  conditions differ from the Company's
assumptions, 
actual  results  and  actions  may  differ from those
anticipated.
MorphoSys  does not intend to update  any of these
forward-looking statements as far as the wording of the relevant press
release is concerned. 
Media Release (PDF): 
http://hugin.info/130295/R/1700768/561397.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: MorphoSys AG via Thomson Reuters ONE 
[HUG#1700768] 
For more information, please contact: 
MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122 
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454 
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332 
investors@morphosys.com
 
 
Press spacebar to pause and continue. Press esc to stop.